KU-55933 (ATM Kinase Inhibitor)

Catalog No.S1092

KU-55933 (ATM Kinase Inhibitor) Chemical Structure

Molecular Weight(MW): 395.49

KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.

Size Price Stock Quantity  
In DMSO USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 36 Publications

4 Customer Reviews

  •  

    Effects of NVP-BKM120 and KU-55933 and their combination on the DNA damage response. A, HCC1937 cells were treated for 18 hours with NVP-BKM120 at 2.5 μmol/L, KU-55933 at 10 μmol/L, or their combination, subjected to ionizing radiation(IR) with 10 Gy or mock, lysed 6 hours later, and subjected to immunoblotting with antibodies as indicated.

    Cancer Discov 2012 2, 1048-1063. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

    Confocal immunostaining (left panel) graphical representation (right panel) for phosphorylation of S25-53BP1, which is known to be ATM dependent, at different time points following irradiation of HEK 293T parental and p18CycE-expressing cells in the absence or presence of the ATM inhibitor, KU55933. Error bars represent SD (n=3).

    Nucleic Acids Res 2011 41, 10157-69. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

  •  

    59PDb2 repression is restored in c22 by inhibition of DNAPKcs. Shown are representative ChIP QPCR of USF-1 binding at Db2 (A) and Db2 mRNA levels (B) in P5424-c22 1 d after treatment with the indicated kinase inhibitors.

    J Immunol 2012 188, 2266-2275. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

    effect of ATM inhibitor in etoposide-induced cell death. The cells were pretreated with KU55933 (2 μM) for 1 h before etoposide treatment.

     

     

    J Biol Chem 2011 286, 8394-8404. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

Purity & Quality Control

Choose Selective ATM/ATR Inhibitors

Biological Activity

Description KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.
Targets
ATM [1]
(Cell-free assay)
12.9 nM
In vitro

KU-55933 inhibits DNA-PK and PI3K with IC50 of 2.5 μM and 16.6 μM, respectively. Besides, KU-55933 also prevents the activity of mTOR with IC50 of 9.3 μM. KU-55933 is active at the cellular level in ablating a well-characterized ATM-dependent phosphorylation event. KU-55933 has a dose-dependent effect in inhibiting this ATM-dependent phosphorylation event with IC50 of 300 nM. KU-58050 does not prevent the ATM-dependent phosphorylation of p53 serine 15 until a dose of 30 μM. Addition of KU-55933 has no appreciable effects on UV-induced phosphorylation of H2AX on serine 139, NBS1 on serine 343, CHK1 on serine 345, and SMC1 on serine 966. In stark contrast to the UV responses, KU-55933 ablates the ionizing radiation-induced phosphorylation of these ATM substrates. KU-55933 sensitizes HeLa cells to a range of ionizing radiation doses. [1] KU-55933 inhibits the phosphorylation of Akt induced by growth factors in cancer cells. KU-55933 suppresses the proliferation of cancer cells. Furthermore, suppression of ATM by KU-55933 improves survival, probably via prevention of downstream activation of TAp63α. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DU-145 NInJemRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknhTWM2OD1|LkK3N|UzKM7:TR?= NXr4RpFlW0GQR1XS
HuO-3N1 NWG2cJF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVT3ZVBPUUN3ME20MlE4OTR{IN88US=> NH7jNFVUSU6JRWK=
LAMA-84 MlX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LsR2lEPTB;ND61PFQ3PSEQvF2= NIrCeYVUSU6JRWK=
CAL-72 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTVwNEiwPFQh|ryP MmfIV2FPT0WU
LoVo MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTZwOUOyN|kh|ryP MlnXV2FPT0WU
HH MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1K4fGlEPTB;OD6yO|Y4OSEQvF2= NES0bVRUSU6JRWK=
SK-MEL-3 M37jUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRThwMki1O|Uh|ryP MVzTRW5ITVJ?
KM12 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HkfmlEPTB;OT6yNVE1OiEQvF2= MmXIV2FPT0WU
NCI-H1437 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXWw[YRIUUN3ME25MlgxQTdizszN MXrTRW5ITVJ?
NCI-H1838 NXXvcVNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzGTWM2OD1zMT6xPFY2KM7:TR?= MUPTRW5ITVJ?
J-RT3-T3-5 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LOOGlEPTB;MUGuNlQyPyEQvF2= NX65XWZYW0GQR1XS
GOTO M1:yTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jOOmlEPTB;MUGuOlk6PiEQvF2= MmjHV2FPT0WU
LB2241-RCC NVfHR4tRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTFzLkexPFYh|ryP NUG5e3lIW0GQR1XS
ES7 MoHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTFzLke4PEDPxE1? Mly1V2FPT0WU
KP-N-YS NEDPV2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTF{Lk[zOVQh|ryP NGjJWnFUSU6JRWK=
CAL-12T M1;YfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;WV2tKSzVyPUGzMlYyPyEQvF2= M2DL[3NCVkeHUh?=
COLO-684 M3\Fdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Wz[GlEPTB;MUSuNVU3QSEQvF2= M{XFWnNCVkeHUh?=
DOK MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnpTWM2OD1zNT6zN|I6KM7:TR?= M1XS[HNCVkeHUh?=
Hs-578-T MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFr3S3RKSzVyPUG1MlQyQDJizszN M1XtcnNCVkeHUh?=
D-423MG NWH3UoxJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTF3LkWyN|Yh|ryP NXW4WZA6W0GQR1XS
DBTRG-05MG NFjFXGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;xbWlEPTB;MUWuOlEyOSEQvF2= M2\iNXNCVkeHUh?=
VM-CUB-1 M1GxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3teVhuUUN3ME2xOU46QDR7IN88US=> MV;TRW5ITVJ?
KG-1 NEDKPFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrpUJpuUUN3ME2xOk4xQTl4IN88US=> M3v6[3NCVkeHUh?=
8305C M4\UZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPpSGFKSzVyPUG2MlE5QDlizszN NImzO3lUSU6JRWK=
HuH-7 NWn0fnJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HBV2lEPTB;MU[uNlY4PCEQvF2= M{\2WHNCVkeHUh?=
LXF-289 M3TLdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn6yTWM2OD1zNj6yO|Q4KM7:TR?= MnHxV2FPT0WU
NCI-H1793 NI\scnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTF4LkS3NVIh|ryP NYnzZ5pCW0GQR1XS
ChaGo-K-1 NWraTGVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3oXWNKSzVyPUG2MlY2PjhizszN MUDTRW5ITVJ?
GCIY M3jFdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XrfWlEPTB;MU[uO|kxPSEQvF2= MWPTRW5ITVJ?
SK-MEL-28 M2HlRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVz4O4dFUUN3ME2xO{4xPDd3IN88US=> NHTlOJRUSU6JRWK=
NCI-SNU-1 Mn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mon2TWM2OD1zNz6xNlY6KM7:TR?= M13hOXNCVkeHUh?=
CTB-1 M{Lucmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zrdmlEPTB;MUeuNlI2QSEQvF2= NFTpb5dUSU6JRWK=
NCI-H82 NGLrNZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHuenVSUUN3ME2xO{41PTd|IN88US=> MYfTRW5ITVJ?
HCC2998 M{S1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13OTGlEPTB;MUeuOlc{OyEQvF2= M1XHU3NCVkeHUh?=
NCI-H2030 M4j2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEH1OlhKSzVyPUG4MlE6QTdizszN NXzNN41QW0GQR1XS
HuP-T3 NEPSdZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXj1ZWdHUUN3ME2xPE42QDh6IN88US=> MXTTRW5ITVJ?
697 NXu1WVJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[4TWM2OD1zOT6wNlAyKM7:TR?= MXTTRW5ITVJ?
MLMA Mo\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mne4TWM2OD1zOT6wOVU4KM7:TR?= M1HyNXNCVkeHUh?=
HCC70 NWTEO3RQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPJfW5WUUN3ME2xPU41QDlizszN NXrXZnBCW0GQR1XS
A704 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PWcGlEPTB;MUmuPFMxPSEQvF2= NFrKfJBUSU6JRWK=
D-283MED MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELNd3FKSzVyPUKwMlU{OzlizszN MlLUV2FPT0WU
U031 MlPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJzLkG0PFkh|ryP NWXO[WVYW0GQR1XS
HSC-3 M2rmN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTJzLkG4N|Uh|ryP MVXTRW5ITVJ?
JVM-3 MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTJ{LkWwOkDPxE1? NVzrRVA2W0GQR1XS
Mewo MmnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml70TWM2OD1{Mj61NFc{KM7:TR?= NGTO[4RUSU6JRWK=
YH-13 M2rzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[xTWM2OD1{Mj61NVI{KM7:TR?= MXzTRW5ITVJ?
LB1047-RCC MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nhdGlEPTB;MkKuOVg4QSEQvF2= MXzTRW5ITVJ?
HCC2157 M4\GUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIC0PIFKSzVyPUKyMlgxPTRizszN M1u0VHNCVkeHUh?=
SNU-449 NHPOdZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnhV3BTUUN3ME2yNk45PzR6IN88US=> NH:4cJdUSU6JRWK=
Ramos-2G6-4C10 NFH1XYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[xepJKSzVyPUKyMlk3KM7:TR?= NH3VdnJUSU6JRWK=
CHL-1 NYH0WoZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYT1dopkUUN3ME2yN{44Ojl{IN88US=> M4rTUXNCVkeHUh?=
SK-MEL-30 NXPvWm9kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGC3PGxKSzVyPUK0MlQ3PjJizszN NHXHUodUSU6JRWK=
PANC-08-13 NWrtZphsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLNXI1XUUN3ME2yOU4xQTN6IN88US=> NVvvfllFW0GQR1XS
QIMR-WIL M1\GNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfCbm9MUUN3ME2yOU4yQDV6IN88US=> M4ridnNCVkeHUh?=
BFTC-905 NH7uVVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrzR45lUUN3ME2yOU42QTR2IN88US=> NGHzbXZUSU6JRWK=
GI-1 M1jaVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:5TWM2OD1{NT63NFU2KM7:TR?= MoHYV2FPT0WU
MDA-MB-415 MnLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXDXmJKSzVyPUK2MlUxOzNizszN MmjWV2FPT0WU
GT3TKB NFXqT4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;HTmlEPTB;Mk[uOVM1OiEQvF2= NXzRSlZwW0GQR1XS
DEL NXLVN2NDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\UUWlEPTB;Mk[uPFM2PiEQvF2= NUHCNmlzW0GQR1XS
KOSC-2 NYi1XI1DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zJbmlEPTB;Mk[uPVA4PSEQvF2= M3ixbnNCVkeHUh?=
RVH-421 M4noNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTJ5LkK5NlEh|ryP MV3TRW5ITVJ?
EW-13 MkXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnzTWM2OD1{Nz60N|A5KM7:TR?= NIHzfm9USU6JRWK=
639-V M2Ls[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXmS2ZKSzVyPUK3MlUyOTlizszN M{\wdXNCVkeHUh?=
A2780 NF:3cIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTJ5Lk[0NUDPxE1? NVLIPJl5W0GQR1XS
SW982 Ml\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzpTWM2OD1{Nz65NFUzKM7:TR?= NGTJO5NUSU6JRWK=
SW1710 M2PlOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHETWM2OD1{OD6wPVgyKM7:TR?= NFXqcWhUSU6JRWK=
HCC1569 MnjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHkTWM2OD1{OD60PFk4KM7:TR?= MmLCV2FPT0WU
MV-4-11 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHpS5pxUUN3ME2yPE42PzN3IN88US=> NE[1TW1USU6JRWK=
BHT-101 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTJ6Lk[1O|Ih|ryP M13GOXNCVkeHUh?=
Ca9-22 M1ixNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHjTWM2OD1{OD63NVQh|ryP NF\xd3BUSU6JRWK=
HAL-01 MmTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTJ6Lke2NVUh|ryP M3TNTXNCVkeHUh?=
D-263MG NUfIWYJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoX2TWM2OD1{OT6zOFQh|ryP MoDoV2FPT0WU
NEC8 MmntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTJ7LkW1OFgh|ryP M3;CfHNCVkeHUh?=
EKVX NXjITZdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETjbWVKSzVyPUOxMlU5PDdizszN MnPQV2FPT0WU
EM-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTNzLk[zNFQh|ryP M3LndnNCVkeHUh?=
MFM-223 NF\uR4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2eyb2lEPTB;M{GuPFA6QCEQvF2= NEnjWVhUSU6JRWK=
SK-PN-DW MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLwUXluUUN3ME2zNk4yPDB4IN88US=> MULTRW5ITVJ?
HuO9 M1jtPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTKW3p3UUN3ME2zNk42Ojh{IN88US=> MmTtV2FPT0WU
MHH-PREB-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnnTWM2OD1|Mj62NlM1KM7:TR?= MUXTRW5ITVJ?
OVCAR-4 M4GzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTN{LkizOlMh|ryP MVHTRW5ITVJ?
NCI-H1648 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTN{Lki2OVEh|ryP MW\TRW5ITVJ?
MKN1 MnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjBPFJEUUN3ME2zOE4yOTBzIN88US=> NHfQVlNUSU6JRWK=
KYSE-450 M4fybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fsWGlEPTB;M{SuOlQ1PCEQvF2= MlnkV2FPT0WU
ES8 MoH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTN2Lki5O|Uh|ryP NWHNcYZoW0GQR1XS
MS-1 MkjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTN2Lkm1OVQh|ryP MX\TRW5ITVJ?
HOP-92 NFy3Nm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrtTWM2OD1|NT65Nlc4KM7:TR?= NH;mSopUSU6JRWK=
SKG-IIIa NHP1dlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTN4LkK1OlEh|ryP MmX6V2FPT0WU
TE-11 M{Pjbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlftTWM2OD1|Nj61NlQ{KM7:TR?= NUDXdlk1W0GQR1XS
SK-NEP-1 M4\VWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTN5Lk[3OFQh|ryP MlK2V2FPT0WU
DB NXfDe3ZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkOyTWM2OD1|Nz65NVg2KM7:TR?= MVnTRW5ITVJ?
IA-LM MmDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTLTWM2OD1|OD6wNlM6KM7:TR?= MYHTRW5ITVJ?
COLO-829 MkDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTN6LkSxOVkh|ryP NH\DdnZUSU6JRWK=
TGBC11TKB MmHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDzXox[UUN3ME2zPU4yPDB6IN88US=> NXrTNox7W0GQR1XS
CAL-51 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTRyLkC2NVIh|ryP MlO2V2FPT0WU
NCI-H2228 M1O5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTRyLkO2OlIh|ryP MVHTRW5ITVJ?
C32 M4Po[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjjbVd7UUN3ME20NE41ODJ2IN88US=> NYHkT3U6W0GQR1XS
KU-19-19 NGPBWFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTlV5lCUUN3ME20NE44Pjh|IN88US=> NXrjT5lyW0GQR1XS
KNS-62 M1Hs[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTRyLkizPFEh|ryP MoTpV2FPT0WU
FADU MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\ZTWM2OD12MT6yOVAzKM7:TR?= MkXYV2FPT0WU
CAL-33 NFnhNmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jSOWlEPTB;NEKuOlc1QSEQvF2= NITWepRUSU6JRWK=
CHP-134 M17EZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4ezXWlEPTB;NEKuPFQ6PiEQvF2= M4LB[3NCVkeHUh?=
HDLM-2 NWPkNpdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTEbJBKSzVyPUSyMlkxQDRizszN M1PibXNCVkeHUh?=
NBsusSR MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH:0[oFKSzVyPUSzMlA4OjVizszN NICyXpNUSU6JRWK=
SW954 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTR|LkGwOVMh|ryP NWHNSY5uW0GQR1XS
HCC1806 MmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\5fWlEPTB;NEOuOFEyKM7:TR?= M{jVNHNCVkeHUh?=
VMRC-RCZ MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\SemlEPTB;NEOuOFU5PiEQvF2= M1Pt[XNCVkeHUh?=
A549 NEHvNlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;JSHlpUUN3ME20N{46OzFizszN MVjTRW5ITVJ?
NKM-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnkTWM2OD12Mz65OVU5KM7:TR?= M4TPS3NCVkeHUh?=
DMS-273 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTR2Lke1Olch|ryP NVKySWJEW0GQR1XS
TYK-nu NG\jb2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHUTWM2OD12NT6xNlM1KM7:TR?= NWnFSZVvW0GQR1XS
KALS-1 NILNTllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTR3LkG0OkDPxE1? M2DJUnNCVkeHUh?=
A101D Mn;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnlRlRPUUN3ME20OU41PDV4IN88US=> M4fZVXNCVkeHUh?=
G-361 NUe2[XMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PDemlEPTB;NE[uNlE{QCEQvF2= MVPTRW5ITVJ?
KARPAS-299 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPzNIhKSzVyPUS2MlM2OTZizszN NVHJellNW0GQR1XS
RS4-11 NEX1S3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2m3cmlEPTB;NE[uOVQzKM7:TR?= NWjKPVFZW0GQR1XS
HT-1376 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILRd5FKSzVyPUS2Mlc1OjZizszN MXTTRW5ITVJ?
SK-N-AS NI\PSJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfnUZdKSzVyPUS2Mlc5OjJizszN MkDXV2FPT0WU
MG-63 MoTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnY[pNKSzVyPUS2MlkxOzZizszN MlfkV2FPT0WU
EPLC-272H MljQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTR4Lkm1NFMh|ryP NGPCWYhUSU6JRWK=
BALL-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGm2SZhKSzVyPUS3Mlg{OiEQvF2= NEO0d5BUSU6JRWK=
LCLC-97TM1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYD0Z3ZVUUN3ME20PE4zODJizszN MoSxV2FPT0WU
HO-1-N-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XH[mlEPTB;NEiuPVY4PiEQvF2= MXLTRW5ITVJ?
MFE-280 NIDDeIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvS[2xKSzVyPUS5MlQ3OTdizszN M4W5PXNCVkeHUh?=
NCI-H526 NH3lNmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGX2Om1KSzVyPUS5MlgyPjNizszN M{DibXNCVkeHUh?=
D-566MG MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rnPWlEPTB;NEmuPVA6PiEQvF2= NGPSR3BUSU6JRWK=
BB30-HNC MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTR7Lkm0PVgh|ryP NFXlc2xUSU6JRWK=
SK-N-DZ M1nNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjQR5VkUUN3ME21NE4xPDhzIN88US=> MkfYV2FPT0WU
HepG2  Mki2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFuzbmMyOMLizszN NUSwXnpYOjRiaB?= MojQZoxw[2u|IGPDMWlKUTNvaX7keYNm\CCVIIDoZZNmKGG{cnXzeC=> NHjZR3QzPTV{N{GyNy=>
HepG2  MYPGeY5kfGmxbjDBd5NigQ>? NV;SbGNlOTEEoN88US=> NFzjeVUzPCCq NVzZO|gxe3WycILld5NmeyC2aHWgdIhwe3Cqb4L5cIF1cW:wczDv[kBCXE1ib36gV4VzOTl6MTygR4hsOSCxbjDT[ZI{PDVuIFPob|Ihd25iVHjyOlgtKGGwZDDD[IszKG:wIGT5dlE2KGmwZIXj[YQh[nliU1OtTWlKOw>? M{nEUlI2PTJ5MUKz
KATO III  M2PMemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnYNk42NzVxNz61JO69VQ>? NULpeZZ6TE2VTx?= M1HCbIVvcGGwY3XzJJRp\SC2b4jpZ4l1gSCxZjDvcIFx[XKrYh?= MVqyOFg1OTdzOB?=
hTCEpi NFrSfJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXVNYwyOCEQvF2= M2H1[2ROW09? Ml3SdJJmfmWwdIOgeIhmKGO7dH;wZZRpcWNiZX\m[YN1KG:oIFjTWk0y MVmyOFM4ODh|NR?=
MCF10A M2PYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTtVXdSOTBizszN MXuyOEBp M1LtTGROW09? NYnNTpZUeG:2ZX70bYF1\XNidHjlJIN6fG:2b4jpZ4l1gSCxZjDHRS=> MX[yOFE2ODV7NR?=
HL-60  MV;GeY5kfGmxbjDBd5NigQ>? NHHPR|EyOCEQvF2= MoC2NE42KGh? Mnz1SG1UVw>? MYDy[YR2[2W|IIDoc5NxcG:{eXzheIlwdiCxZjDDbIszyqB? MlHSNlM6OzR2MUG=
MCF-7 M37JXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3adIEzOS1zMEFOwG0> MknMNlQhcA>? NYizZndvTkKV M3jsNYlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25? M2fpNVI{OTh3M{S3
HeLa  NUm2UYMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nTdVEuOTByzszN M4DqXlI1KGh? NV20dFFETkKV MofnbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdg>? NX;LW4J6OjNzOEWzOFc>
SH-SY5Y NHvlc4VHfW6ldHnvckBCe3OjeR?= M1O5UFExyqEQvF5CpC=> MW[yOEBp MoeybY5pcWKrdIOgZ4xqd3G3aX7vcE1qdmS3Y3XkJJBpd3OyaH;yfYxifGmxbjDv[kBxPTN? NX;UU|hKOjJ4MkeyPVQ>
IMR-32 MoTMSpVv[3Srb36gRZN{[Xl? MkThNVDDqM7:TdMg MmrrNlQhcA>? MkTnbY5pcWKrdIOgZ4xqd3G3aX7vcE1qdmS3Y3XkJJBpd3OyaH;yfYxifGmxbjDv[kBxPTN? Mm\ONlI3Ojd{OUS=
A549 MlrrSpVv[3Srb36gRZN{[Xl? MV[xNOKh|ryPwrC= MnO5NUBp MV7zeZBxemW|c3XzJG5idm9vQ3:tbY5lfWOnZDDwOVMh[WOldX31cIF1cW:w MmPjNlI2PTl|MkG=
T47D  NWTXOmVsTnWwY4Tpc44hSXO|YYm= M136UlIxyqCvTR?= NEjFT4ozPCCq MXnEUXNQ MVfwdoV3\W62czDJVk1qdmS3Y3XkJIRm\3KjZHH0bY9vKG:oIFpOvmLPuQ>? MWCyNVE1PDhyNR?=
A29 MEF MmrGSpVv[3Srb36gRZN{[Xl? M3XScVExyqEQvF5CpC=> NXTSdpMxOWh? NXzvOYlI[myxY3vzxsB1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHreEBifCCVZYK0O|PDqA>? MmfFNlAxPTN5OEG=
MDA-MB-453  NUfBRlZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TtW|UuPDBizszN NVrRbHpKPzJiaB?= MXzJR|UxKG:oIEGwJO69VQ>? MWWyNFA2Ozd6MR?=
PC-3 NEC1cHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nnPVUuPDBizszN NHnKUYU4OiCq MljETWM2OCCxZjCxNEDPxE1? NEPkfXEzODB3M{e4NS=>

... Click to View More Cell Line Experimental Data

In vivo Suppression of ATM-dependent STAT3 activation by KU-55933 enhances TRAIL-mediated apoptosis through up-regulation of surface DR5 expression, whereas suppression of both STAT3 and NF-κB appeares to be involved in down-regulation of cFLIP accompanied by an additional increase in apoptotic levels. The ATM inhibitor KU-55933 affectes TRAIL-mediated apoptosis more strongly than the JAK2 inhibitor, AG490, or overexpression of STAT3β. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Purified enzyme assays:

ATM for use in the in vitro assay is obtained from HeLa nuclear extract by immunoprecipitation with rabbit polyclonal antiserum raised to the COOH-terminal 400 amino acids of ATM in buffer containing 25 mM HEPES (pH 7.4), 2 mM MgCl2, 250 mM KCl, 500 μM EDTA, 100 μM Na3VO4, 10% v/v glycerol, and 0.1% v/v Igepal. ATM-antibody complexes are isolated from nuclear extract by incubating with protein A-Sepharose beads for 1 hour and then through centrifugation to recover the beads. In the well of a 96-well plate, ATM-containing Sepharose beads are incubated with 1 μg of substrate glutathione S-transferase–p53N66 (NH2-terminal 66 amino acids of p53 fused to glutathione S-transferase) in ATM assay buffer [25 mM HEPES (pH 7.4), 75 mM NaCl, 3 mM MgCl2, 2 mM MnCl2, 50 μM Na3VO4, 500 μM DTT, and 5% v/v glycerol] at 37 °C in the presence or absence of inhibitor. After 10 minutes with gentle shaking, ATP is added to a final concentration of 50 μM and the reaction continued at 37 °C for an additional 1 hour. The plate is centrifuged at 250 × g for 10 minutes (4 °C) to remove the ATM-containing beads, and the supernatant is removed and transferred to a white opaque 96-well plate and incubated at room temperature for 1.5 hours to allow glutathione S-transferase-p53N66 binding. This plate is then washed with PBS, blotted dry, and analyzed by a standard ELISA technique with a phospho-serine 15 p53 antibody. The detection of phosphorylated glutathione S-transferase-p53N66 substrate is performed in combination with a goat antimouse horseradish peroxidase-conjugated secondary antibody. Enhanced chemiluminescence solution is used to produce a signal and chemiluminescent detection is carried out.
Cell Research:

[1]

+ Expand
  • Cell lines: U2OS cells
  • Concentrations: 10 μM
  • Incubation Time: 2 hours
  • Method:

    U2OS cells are exposed to ionizing radiation (3, 5, or 15 Gy) or UV (5 or 50 J/m2) and the ATM response determined by Western blot analysis of p53 serine 15 phosphorylation and stabilization of wild-type p53. Whole cell extracts are obtained from each time point, proteins separated by SDS-PAGE, and the ATM-specific increase in phosphorylated serine 15 measured with a p53 phospho-serine 15 specific antibody. Overall p53 stabilization with time is also observed with a p53-specific antibody (DO-1). Similarly, for studying ATM-dependent phosphorylations on H2AX, CHK1, NBS1, and SMC1, the following antibodies are used: CHK1 phospho-serine 345 and NBS1 phospho-serine 343 antibodies. Histone H2A (H-124) and CHK1 antibodies are also used, as well as SMC1 and SMC1 phospho-serine 966 antibodies. For determination of a cellular IC50 for KU-55933, the peak response time for p53 serine 15 phosphorylation of 2 hours is used to monitor inhibition of ATM. KU-55933 is titrated onto cells and preincubated for 1 hour before ionizing radiation. Using scanning densitometry, the percentage inhibition relative to vehicle control is calculated, and the IC50 value is calculated as for the in vitro determinations.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: BALB/c nu/nu nude mice bearing LU1205 cells
  • Formulation: --
  • Dosages: 10 μM
  • Administration: --
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 33 mg/mL (83.44 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO and 47.5% PEG300
For best results, use promptly after mixing.
10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 395.49
Formula

C21H17NO3S2

CAS No. 587871-26-9
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATM/ATR Signaling Pathway Map

ATM/ATR Inhibitors with Unique Features

Related ATM/ATR Products

Tags: buy KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) supplier | purchase KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) cost | KU-55933 (ATM Kinase Inhibitor) manufacturer | order KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID